Alembic Pharma receives EIR from USFDA
Alembic Pharmaceuticals has received an Establishment Inspection Report from the US health regulator for its formulation facility located at Panelav15-06-2018
15-06-2018
Alembic Pharmaceuticals Limited Receives Establishment Inspection Report (EIR) For Its Formulation Facility At Panelav
This is to inform the exchange that the Company has received Establishment Inspection Report (EIR) from United States Food and Drug Administration (US FDA) for the inspection carried out by them at our Formulation Facility at Panelav during the period from 12th March, 2018 to 20th March, 2018. We request you to kindly take the same on record.15-06-2018
Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Approval for Doxycycline Hyclate Capsules USP, 50 mg and 100 mg. Please find enclosed herewith our press release. We request you to kindly take the same on record.14-06-2018
Alembic Pharma shares surge 20% on USFDA nod for depression drug
The approval is for strengths of 75 mg and 100 mg11-06-2018
Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Approval for Bupropion Hydrochloride Tablets USP, 75 mg and 100 mg. Please find enclosed herewith our press release. We request you to kindly take the same on record.11-06-2018
Change In Company Secretary & Compliance Officer
In continuation to the outcome of Board Meeting dated 16th May, 2018 submitted by us with the Stock Exchanges, we would like to inform the exchange that: 1. Mr. Ajay Kumar Desai, Sr. VP - Finance & Company Secretary has resigned from the position of Company Secretary & Compliance Officer w.e.f. 31st May, 2018 (after close of business hours). Mr. Ajay Kumar Desai will continue with his responsibilities as Sr. VP - Finance....01-06-2018
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Nirayu Pvt Ltd31-05-2018
Disclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Nirayu Pvt Ltd31-05-2018
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Laksh Trust31-05-2018
Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Laksh Trust31-05-2018